Yerly S - Search Results

1

A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.

Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B; Swiss HIV Cohort Study. Fagard C, et al. Among authors: yerly s. Arch Intern Med. 2003 May 26;163(10):1220-6. doi: 10.1001/archinte.163.10.1220. Arch Intern Med. 2003. PMID: 12767960 Free article.

2

Quantitation of human immunodeficiency virus provirus and circulating virus: relationship with immunologic parameters.

Yerly S, Chamot E, Hirschel B, Perrin LH. Yerly S, et al. J Infect Dis. 1992 Aug;166(2):269-76. doi: 10.1093/infdis/166.2.269. J Infect Dis. 1992. PMID: 1353103

3

Absence of chronic human immunodeficiency virus infection without seroconversion in intravenous drug users: a prospective and retrospective study.

Yerly S, Chamot E, Déglon JJ, Hirschel B, Perrin LH. Yerly S, et al. J Infect Dis. 1991 Nov;164(5):965-8. doi: 10.1093/infdis/164.5.965. J Infect Dis. 1991. PMID: 1940476

4

Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users.

Chamot E, Hirschel B, Wintsch J, Robert CF, Gabriel V, Déglon JJ, Yerly S, Perrin L. Chamot E, et al. Among authors: yerly s. AIDS. 1990 Dec;4(12):1275-7. doi: 10.1097/00002030-199012000-00016. AIDS. 1990. PMID: 1965126

5

Development of a haptoglobin ELISA. Its use as an indicator for malaria.

Yerly S, Bouvier M, Rougemont A, Srivastava I, Perrin LH. Yerly S, et al. Acta Trop. 1990 May;47(4):237-44. doi: 10.1016/0001-706x(90)90015-r. Acta Trop. 1990. PMID: 1973025

6

Human immunodeficiency virus DNA amplification and serology in blood donors.

Perrin LH, Yerly S, Adami N, Bachmann P, Bütler-Brunner E, Burckhardt J, Kawashima E. Perrin LH, et al. Among authors: yerly s. Blood. 1990 Aug 1;76(3):641-5. Blood. 1990. PMID: 2198964 Free article.

7

Response of HIV RNA to didanosine as a predictive marker of survival.

Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B, Perrin L. Yerly S, et al. AIDS. 1995 Feb;9(2):159-63. AIDS. 1995. PMID: 7718186

8

Foscarnet decreases human immunodeficiency virus RNA.

Kaiser L, Perrin L, Hirschel B, Furrer H, Von Overbeck J, Olmari M, Yerly S. Kaiser L, et al. Among authors: yerly s. J Infect Dis. 1995 Jul;172(1):225-7. doi: 10.1093/infdis/172.1.225. J Infect Dis. 1995. PMID: 7797916 Clinical Trial.

9

Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine.

Yerly S, Kaiser L, Baumberger C, Hirschel B, Perrin LH. Yerly S, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):358-64. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7882100

10

V3 sequences in primary HIV-1 infection.

Antonioli IM, Baumberger C, Yerly S, Perrin L. Antonioli IM, et al. Among authors: yerly s. AIDS. 1995 Jan;9(1):11-7. doi: 10.1097/00002030-199501000-00002. AIDS. 1995. PMID: 7893436

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

510 results

Search Page